Vucinic Vladan, Quaiser Andrea, Lückemeier Philipp, Fricke Stephan, Platzbecker Uwe, Koehl Ulrike
University of Leipzig, Medical Clinic for Hematology, Cell Therapy and Hemostaseology, Leipzig Medical Center, Leipzig, Germany.
Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Front Med (Lausanne). 2021 Aug 16;8:713401. doi: 10.3389/fmed.2021.713401. eCollection 2021.
Rapid developments in the field of CAR T cells offer important new opportunities while at the same time increasing numbers of patients pose major challenges. This review is summarizing on the one hand the state of the art in CAR T cell trials with a unique perspective on the role that Europe is playing. On the other hand, an overview of reproducible processing techniques is presented, from manual or semi-automated up to fully automated manufacturing of clinical-grade CAR T cells. Besides regulatory requirements, an outlook is given in the direction of digitally controlled automated manufacturing in order to lower cost and complexity and to address CAR T cell products for a greater number of patients and a variety of malignant diseases.
嵌合抗原受体（CAR）T细胞领域的快速发展带来了重要的新机遇，与此同时，患者数量的增加也带来了重大挑战。本综述一方面从欧洲所发挥作用的独特视角总结了CAR T细胞试验的现状。另一方面，介绍了可重复的处理技术概况，从手动或半自动技术到临床级CAR T细胞的全自动化生产。除了监管要求外，还展望了数字控制的自动化生产方向，以降低成本和复杂性，并为更多患者和多种恶性疾病提供CAR T细胞产品。
